Having trouble viewing this email? View it in your browser.
Musella Foundation Logo and Name of Email Blast
Tuesday, November 28, 2023
Issue 5946

NEW: July 2023
The time has come to rally for the Promising Pathway Act!

Click for details and to easily send letters.

Latest News

  • Celebrate 25 Years of Impact with the Musella Foundation This Giving Tuesday        
    Dear Friends and Supporters,
    As we mark our 25th year at the Musella Foundation For Brain Tumor Research and Information, Inc., we invite you to join us in celebrating and supporting our continued efforts against brain tumors this Giving Tuesday.
    A Legacy of Excellence: Over these 25 years, we've made groundbreaking strides in brain tumor research, thanks to your unwavering support. We're proud to share that we've received a 4-star 100% grade from Charity Navigator, reflecting our commitment to transparency and efficacy.
    Decades of Impactful Research: Our journey has led to funding over 180 research grants, totaling more than $6 million, resulting in significant advances, including crucial trials for GBM and new treatments for recurrent GBM.
    Innovative Drug Development: We've played a key role in the development of drugs like ONC201, bringing new hope to DIPG and glioma patients. Our efforts with GB-13 and OKN-007 demonstrate our dedication to finding effective therapies.
    Advocacy for Better Treatment Options: Our advocacy has been pivotal in securing the approval of essential treatments like Temodar, Avastin, Gleolan, and Gliadel. We’ve also helped author the Promising Pathway Act, furthering our commitment to improving treatment options for brain tumor patients.
    Empowering Patients and Families: Our comprehensive resources, including the Brain Tumor Guide, educational webinars, and patient navigation, offer support and guidance to those affected.
    2023 Highlights: For an in-depth look at our 25-year journey and achievements, visit our 2023 Highlights.
    Your Support is Vital: As we reflect on our past and look to the future, your generosity remains crucial. Please join us in our mission this Giving Tuesday.
    How to Donate: Support our cause at virtualtrials.org/donate or by mailing a check to Musella Foundation, 1100 Peninsula Blvd, Hewlett, NY 11557. Every contribution counts!
    Join us in celebrating 25 years of progress and commitment to brain tumor research and patient support. Thank you for being part of our journey.
    Warm regards,
    Al Musella, DPM
    Musella Foundation For Brain Tumor Research and Information, Inc.

  • Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology        

     Impressive results from one treatment of Bizaxofusp for recurrent Glioblastoma. The survival at 1 year increased 370% compared to a well matched external control group.  They think this treatment may stimulate the immune system which may make a combination with a checkpoint inhibitor logical.  

  • CAR-T cell therapies infused into brain shrink tumors in two glioblastoma studies        

     This is way too early but looks very promising.  CAR-T cells were a major breakthrough for other types of cancer but until now have not really worked well with brain tumors.  Many researchers are working on ways of making them work for brain tumor. Here, two groups present the first evidence that there is hope.

Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details

To view past stories go to : https://virtualtrials.org/newsblast.cfm
To submit a story/press release go to: click here To unsubscribe, click here.
The article commentaries are the opinions of Al Musella, DPM and do not represent the official position of the Musella Foundation. Copyright 1992-2023 Musella Foundation - All rights reserved. No part of the Brain Tumor News Blast can be reproduced without the express written permission of the Musella Foundation.